March 4, 2026Japanese Journal of Clinical Oncology0 citations
Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma
The study aims to evaluate the effectiveness and safety of third-line therapy after prior treatments in advanced renal cell carcinoma.
Analyzed real-world patient outcomes following third-line treatment.
Investigated the sequence of immune checkpoint inhibitors and VEGFR-TKIs.
Assessed toxicity and clinical effectiveness of the treatments.
Third-line therapy demonstrated feasibility with effective clinical outcomes.
Toxicity levels were manageable among treated patients.
Overall treatment strategy showed promise for advanced RCC management.
Abstract
Third-line systemic therapy following ICI combinations and sequential VEGFR-TKIs shows feasible clinical effectiveness and manageable toxicity in real-world patients with advanced RCC.